Mylan Launches Gilead Sciences' Sovaldi Tablets in India

Mylan N.V. MYL today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched Gilead Sciences' GILD Sovaldi (sofosbuvir 400mg tablets) in India. Sovaldi is indicated for the treatment of chronic hepatitis C infection, a blood-borne infectious disease, as a component of a combination antiviral treatment regimen. It is estimated that approximately 12 million people are chronically infected with hepatitis C in India.